Bioflow-DAPT Study
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1948 participants.
Also called NCT04137510
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,948 participants
- Sponsor
- Registry
-
NCT04137510
-
- Other papers using this trial's data
- Biodegradable polymer sirolimus-eluting or durable polymer zotarolimus-eluting stents in high bleeding-risk patients with acute coronary syndrome: the BIOFLOW-DAPT randomized trial
- Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Australia, Austria, Belgium, Denmark, France, Germany, Hong Kong SAR China, Hungary, Italy, Latvia, Malaysia, Netherlands, New Zealand, Poland, Singapore, Spain, Switzerland, Thailand
- Registry status
- Completed
Technical summary
Registry record NCT04137510. Randomized; no masking; primary purpose treatment. Start 2020-02-24 (actual); primary completion 2022-09-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Bioflow-DAPT Study
- Condition
- Coronary Artery Disease
- Intervention (Device)
- Percutaneous coronary intervention
- Lead sponsor
- Biotronik AG
Record details
- Record id
cardio:ct-nct04137510- Content hash
48fdb509fded3c097a911ce3f1379215d32b814c603b82fc12a112fcb45d8be8